Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics

scientific article published on 24 September 2015

Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S2213-2600(15)00255-6
P698PubMed publication ID26411809
P5875ResearchGate publication ID282343746

P50authorShabir A. MadhiQ56065756
Asuncion MejiasQ56487386
Harish NairQ61081121
Mike SharlandQ61094965
Terho HeikkinenQ38590173
Federico Martinón-TorresQ41491268
Anne GreenoughQ43412070
P2093author name stringLouis Bont
Nikolaos G Papadopoulos
Paolo Manzoni
Brigitte Fauroux
Fernando P Polack
Octavio Ramilo
Eugenio Baraldi
Renato Stein
Natalie I Mazur
Respiratory Syncytial Virus Network (ReSViNET)
P2860cites workDevelopment and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantQ21091066
Bronchodilators for bronchiolitisQ24193936
Nebulised hypertonic saline solution for acute bronchiolitis in infantsQ24200958
Glucocorticoids for acute viral bronchiolitis in infants and young childrenQ24202303
Epinephrine for bronchiolitisQ24236688
Grading quality of evidence and strength of recommendationsQ24562409
Duration of symptoms of respiratory tract infections in children: systematic reviewQ24615215
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Q26782024
The role of early life viral bronchiolitis in the inception of asthmaQ26851823
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersQ27667876
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyQ27677570
Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genesQ28241147
Identification of nucleolin as a cellular receptor for human respiratory syncytial virusQ28245563
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisQ29619821
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitisQ30423684
The source of respiratory syncytial virus infection in infants: a household cohort study in rural KenyaQ33596091
Pharmacologic advances in the treatment and prevention of respiratory syncytial virusQ33776507
Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memoryQ34059404
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteersQ34079756
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccineQ34206177
Direct medical costs of bronchiolitis hospitalizations in the United States.Q50793631
Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.Q51657773
High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study.Q53602713
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.Q55053023
Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?Q87170350
Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitisQ34445159
Diagnosis and management of bronchiolitisQ34570865
Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancyQ34778067
The burden of respiratory syncytial virus infection in young childrenQ34938343
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthmaQ34987105
Frequent Asymptomatic Respiratory Syncytial Virus Infections During an Epidemic in a Rural Kenyan Household CohortQ36250186
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse geneticsQ36276526
Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperatureQ36607430
Determinants of asthma after severe respiratory syncytial virus bronchiolitisQ36729353
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageQ37265589
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adultsQ37335667
Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromesQ37570912
Strategic priorities for respiratory syncytial virus (RSV) vaccine developmentQ37572640
Medicines used in respiratory diseases only seen in childrenQ37589992
Diagnosis, management, and prognosis of preschool wheezeQ38209053
Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trialQ38425193
Nebulized hypertonic saline for bronchiolitis: a randomized clinical trialQ38429619
Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trialQ38429626
Oral GS-5806 activity in a respiratory syncytial virus challenge study.Q42198937
Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infantsQ42207500
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.Q42248000
Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011.Q42251265
Respiratory syncytial virus and recurrent wheeze in healthy preterm infantsQ42263767
Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.Q42282088
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccineQ43625547
Bronchiolitis management before and after the AAP guidelinesQ43766700
Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trialQ45158454
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).Q45397417
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trialQ45458064
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 yearsQ45747463
High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study.Q46243372
Bronchiolitis-associated hospitalizations among US children, 1980-1996.Q50653027
P433issue11
P921main subjectmaternal healthQ6786626
P304page(s)888-900
P577publication date2015-09-24
P1433published inThe Lancet. Respiratory medicineQ27724908
P1476titleLower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics
P478volume3

Reverse relations

cites work (P2860)
Q38849066A clustering approach to identify severe bronchiolitis profiles in children
Q56794662A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats
Q39027049Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection
Q90690359Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
Q95283540Advanced "lab-on-a-chip" to detect viruses - Current challenges and future perspectives
Q90024114An ethics framework and practical guidance for post-trial access to an RSV maternal vaccine
Q91656519Anti-Respiratory Syncytial Virus Activity of Plantago asiatica and Clerodendrum trichotomum Extracts In Vitro and In Vivo
Q39028034Best practices in the treatment of early cystic fibrosis lung disease
Q28551925Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase
Q47562812Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts
Q98735544Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV
Q53693691Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.
Q96436602Chemokine (C-X-C motif) Ligand 4 is a Restrictor of Respiratory Syncytial Virus Infection and an Indicator of Clinical Severity
Q39294045Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children
Q42362274Community-acquired pneumonia in children - a changing spectrum of disease
Q49728845Comparison of the prevalence of respiratory viruses in patients with acute respiratory infections at different hospital settings in North China, 2012-2015.
Q45324366Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
Q50793129Deciphering clinical phenotypes in acute viral lower respiratory tract infection: Bronchiolitis is not an island.
Q28067464Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease
Q40060466Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?
Q38969434Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
Q59357659Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability
Q47392075Discharge Criteria for Bronchiolitis: An Unmet Need
Q28076551Early-life respiratory infections and asthma development: role in disease pathogenesis and potential targets for disease prevention
Q36169484Epidemiology and Clinical Presentations of Respiratory Syncytial Virus Subgroups A and B Detected with Multiplex Real-Time PCR
Q54610317Establishment of childhood pneumonia cause in the era of pneumococcal conjugate vaccines.
Q36275637Etiology of severe pneumonia in Ecuadorian children
Q59353230Exchange Proteins Directly Activated by cAMP and Their Roles in Respiratory Syncytial Virus Infection
Q37049972Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts
Q30148692Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance
Q40040542Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series
Q38687853Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Q38752668Heme Oxygenase-1 Modulates Human Respiratory Syncytial Virus Replication and Lung Pathogenesis during Infection
Q38657710Identification of two novel functional tRNA-derived fragments induced in response to respiratory syncytial virus infection
Q40043100Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines
Q98775560Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions
Q59355642Increased severity of respiratory syncytial virus airway infection due to passive smoke exposure
Q29248088Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods
Q60954877Innate Immune Cell Suppression and the Link With Secondary Lung Bacterial Pneumonia
Q96680272Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy
Q38744226Latest options for treatment of bronchiolitis in infants
Q37719544Management of acute respiratory diseases in the pediatric population: the role of oral corticosteroids
Q46622417Meeting Report: Harmonization of RSV therapeutics – from design to performance
Q59350800Metabolomic profiling of infants with recurrent wheezing after bronchiolitis
Q47548281Molecular epidemiology of human respiratory syncytial virus among children in Japan during three seasons and hospitalization risk of genotype ON1.
Q53601809Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries.
Q100407560Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial
Q40403859New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners.
Q88290056Otitis media
Q39318498Passive and active immunization against respiratory syncytial virus for the young and old.
Q90580234Pharmacokinetics, Safety and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized with RSV Infection: A Randomized Phase 1b Study
Q38941657Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects
Q92640553Prescribing for bronchiolitis: think globally, choose wisely
Q90953271Prevalence of infant bronchiolitis-coded healthcare encounters attributable to RSV
Q39967767Prevalence, codetection and seasonal distribution of upper airway viruses and bacteria in children with acute respiratory illnesses with cough as a symptom.
Q40110283Promising approaches for the treatment and prevention of viral respiratory illnesses
Q47554686Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review.
Q40332252Respiratory Syncytial Virus (RSV) Infects CD4+ T Cells: Frequency of Circulating CD4+ RSV+ T Cells as a Marker of Disease Severity in Young Children
Q64894378Respiratory Syncytial Virus Seasonality, Beijing, China, 2007-2015.
Q57461131Respiratory Syncytial Virus-induced Acute Disease Severity and Long-Term Wheezing. Uncovering the Unexpected
Q30240274Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Q50143928Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium.
Q37577700Respiratory syncytial virus infection: an innate perspective
Q49817370Respiratory syncytial virus is an "opportunistic" killer
Q40933386Respiratory syncytial virus trials and beyond
Q38803541Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
Q39198689Respiratory syncytial virus-Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life.
Q38888943Review of the clinical significance of respiratory virus infections in newborn infants
Q41922224Role of viral infections in the development and exacerbation of asthma in children
Q54299508Seasonal immunisation against respiratory syncytial virus disease.
Q40419642Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children
Q58778749Surveillance for respiratory syncytial virus and parainfluenza virus among patients hospitalized with pneumonia in Sarawak, Malaysia
Q40096615The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification
Q55473370The impact of modifiable risk factor reduction on childhood asthma development.
Q57026345The impact of respiratory viruses on lung health after preterm birth
Q59358526The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Q38789297The role of the NxTAG® respiratory pathogen panel assay and other multiplex platforms in clinical practice
Q38650711Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Q40051899Tissue compartmentalization of T cell responses during early life
Q47549703Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses
Q57019179Viral Sepsis in Children
Q30248348Viral bronchiolitis.
Q64375170Viral pathogens associated with acute lower respiratory tract infections in children younger than 5 years of age in Bulgaria
Q39199043Viruses in cystic fibrosis patients' airways
Q45324472Whole Exome Sequencing reveals new candidate genes in host genomic susceptibility to Respiratory Syncytial Virus Disease.

Search more.